23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Revolution Medicines, Inc. › 2025-2026

Revolution Medicines, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Revolution Medicines, Inc.’s Form 8-K, filed June 22, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 527Asset managers, any item
  • 2,573Fund votes
  • June 18, 2026Meeting date

Results at a glance

Meeting of June 18, 2026: 4 items on Revolution Medicines, Inc.’s Form 8-K, filed June 22, 2026: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 1 director (20.9% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Revolution Medicines, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Revolution Medicines, Inc.

These tallies are Revolution Medicines, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Revolution Medicines, Inc. — official shareholder meeting results, meeting held June 18, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Alexis Borisy 127,181,172---- 33,660,53220,813,641 79%Passed (calculated)—
Elect Director: Mark A. Goldsmith, M.D., Ph.D. 157,681,628---- 3,160,07620,813,641 98%Passed (calculated)—
2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 181,309,783206,306139,256 ---- 99.9%Approved—
3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC 155,110,8255,554,146176,733 --20,813,641 97%Approved—

Source: Revolution Medicines, Inc., Form 8-K, filed with the SEC on June 22, 2026 — read the filing on EDGAR.

How asset managers voted at the Revolution Medicines, Inc. 2025-2026 meeting

527 asset managers disclosed a vote on at least one Revolution Medicines, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Alexis Borisy

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 8 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 127,181,172WITHHELD: 33,660,532
Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis Borisy

Revolution Medicines, Inc.’s own tally for this item (“Elect Director: Alexis Borisy”): 127,181,172 for, 33,660,532 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 118 asset managers below reported 48,055,920 for, 3,764,484 withheld, 391,920 abstained, 235 not voted.

FOR
FOR: 48,055,920ABSTAIN: 391,920WITHHOLD: 3,764,484NOT VOTED: 235
Largest asset managers voting on “To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his suc” at Revolution Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,352,0240 9110,603For
Fidelity9,665,8430 00For
JANUS INVESTMENT FUND4,020,1580 01,001,496Mixed
BlackRock4,194,8170 00For
T. Rowe Price2,563,0780 00For
Charles Schwab1,843,9910 00For
State Street1,8090 0939,088Withhold
Columbia Threadneedle869,2240 00For
Capital Group794,6870 00For
Lord Abbett707,7000 00For
Franklin Custodian Funds400,0000 00For
Dimensional00 0350,840Withhold
Victory Capital3700 0324,264Withhold
TIAA313,9070 00For
FRANKLIN STRATEGIC SERIES287,0360 00For
JANUS ASPEN SERIES265,5400 05,677For
Invesco260,2730 00For
MUTUAL FUND SERIES TRUST257,2180 00For
American Century00 0239,067Withhold
MARSICO INVESTMENT FUND219,4600 00For
Jackson National113,0730 106,0990Mixed
Goldman Sachs203,0290 02,940For
MFS00 0187,214Withhold
Bridge Builder Trust28,4640 112,5110Mixed
Equitable100,5050 036,639Mixed

Showing the 25 largest of 118 asset managers. All 118 are in the interactive database (link above).

Elect Director: Mark A. Goldsmith, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 10 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 157,681,628WITHHELD: 3,160,076
Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Mark A. Goldsmith, M.D., Ph.D.

Revolution Medicines, Inc.’s own tally for this item (“Elect Director: Mark A. Goldsmith, M.D., Ph.D.”): 157,681,628 for, 3,160,076 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 118 asset managers below reported 51,644,052 for, 498,940 withheld, 69,332 abstained, 235 not voted.

FOR
FOR: 51,644,052ABSTAIN: 69,332WITHHOLD: 498,940NOT VOTED: 235
Largest asset managers voting on “To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his suc” at Revolution Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,362,7060 110For
Fidelity9,665,8430 00For
JANUS INVESTMENT FUND5,021,6540 00For
BlackRock4,194,8170 00For
T. Rowe Price2,563,0780 00For
Charles Schwab1,843,9910 00For
State Street940,8880 09For
Columbia Threadneedle869,2240 00For
Capital Group794,6870 00For
Lord Abbett707,7000 00For
Franklin Custodian Funds400,0000 00For
Dimensional00 0350,840Withhold
Victory Capital324,6340 00For
TIAA313,9070 00For
FRANKLIN STRATEGIC SERIES287,0360 00For
JANUS ASPEN SERIES271,2170 00For
Invesco260,2730 00For
MUTUAL FUND SERIES TRUST257,2180 00For
American Century239,0670 00For
MARSICO INVESTMENT FUND219,4600 00For
Jackson National216,0630 3,1090For
Goldman Sachs205,9690 00For
MFS187,2140 00For
Bridge Builder Trust140,9750 00For
Equitable100,5050 036,639Mixed

Showing the 25 largest of 118 asset managers. All 118 are in the interactive database (link above).

On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 19 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 155,110,825AGAINST: 5,554,146

Prior year: 98.2% for (June 26, 2025 meeting) ▼ 1.7 pts

Details: description as filed, official tally, votes by 527 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").

Revolution Medicines, Inc.’s own tally for this item (“3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC”): 155,110,825 for, 5,554,146 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 118 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as di” at Revolution Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,346,99613 00For
Fidelity9,665,8430 00For
JANUS INVESTMENT FUND5,021,6540 00For
BlackRock4,194,8170 00For
T. Rowe Price2,513,25349,825 00For
Charles Schwab1,843,9910 00For
State Street940,530367 00For
Columbia Threadneedle869,2240 00For
Capital Group0794,687 00Against
Lord Abbett707,7000 00For
Franklin Custodian Funds400,0000 00For
Dimensional350,8400 00For
Victory Capital324,6340 00For
TIAA313,9070 00For
FRANKLIN STRATEGIC SERIES287,0360 00For
JANUS ASPEN SERIES271,2170 00For
Invesco0260,273 00Against
MUTUAL FUND SERIES TRUST257,2180 00For
American Century0239,067 00Against
MARSICO INVESTMENT FUND219,4600 00For
Jackson National219,1720 00For
Goldman Sachs205,9690 00For
MFS0187,214 00Against
Bridge Builder Trust140,9750 00For
Equitable137,1440 00For

Fund voting reports, all 118 managers: 50,405,969 for, 1,761,274 against, 850 abstained, 235 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 436 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as di” at Revolution Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson21,654,0059,898 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.14,135,2700 00For
Fidelity10,395,0541,279 00For
BlackRock6,737,07528,659 00For
Darwin Global Management, Ltd.5,779,8480 00For
Paradigm Biocapital Advisors LP5,094,4910 00For
Wellington4,408,5100 00For
Nextech Invest Ltd.4,010,7740 00For
State Street3,961,54441,323 00For
T. Rowe Price3,781,57076,880 00For
BVF INC/IL3,581,7820 00For
GEODE CAPITAL MANAGEMENT, LLC3,539,3270 00For
GV Management Company, L.L.C.2,946,6190 00For
Casdin Capital, LLC2,577,3330 00For
Woodline Partners LP2,276,9030 00For
DEERFIELD MANAGEMENT COMPANY, L.P.2,256,1080 00For
Polar Capital Holdings Plc2,144,9540 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.2,088,2740 00For
Charles Schwab1,880,9760 00For
Caligan Partners LP1,583,6520 00For
Vanguard1,481,9440 00For
Holocene Advisors, LP1,407,3440 00For
Rock Springs Capital Management LP1,246,2160 00For
Vestal Point Capital, LP1,231,2980 00For
Logos Global Management LP1,086,7130 00For

Institutional-manager reports, all 436 managers: 132,863,791 for, 4,486,887 against, 380,102 abstained, 3,687 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 181,309,783AGAINST: 206,306

Prior year: 99.9% for (June 26, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 119 asset managers

Description as filed by funds: To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; and

Revolution Medicines, Inc.’s own tally for this item (“2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 181,309,783 for, 206,306 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 119 asset managers below reported 52,167,465 for, 26 against, 850 abstained, 235 not voted.

FOR
FOR: 52,167,465AGAINST: 26ABSTAIN: 850NOT VOTED: 235
Largest asset managers voting on “To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoope” at Revolution Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard19,347,0080 00For
Fidelity9,665,8430 00For
JANUS INVESTMENT FUND5,021,6540 00For
BlackRock4,194,8170 00For
T. Rowe Price2,563,0780 00For
Charles Schwab1,843,9910 00For
State Street940,87126 00For
Columbia Threadneedle869,2240 00For
Capital Group794,6870 00For
Lord Abbett707,7000 00For
Franklin Custodian Funds400,0000 00For
Dimensional350,8400 00For
Victory Capital324,6340 00For
TIAA313,9070 00For
FRANKLIN STRATEGIC SERIES287,0360 00For
JANUS ASPEN SERIES271,2170 00For
Invesco260,2730 00For
MUTUAL FUND SERIES TRUST257,2180 00For
American Century239,0670 00For
MARSICO INVESTMENT FUND219,4600 00For
Jackson National219,1720 00For
Goldman Sachs205,9690 00For
MFS187,2140 00For
Bridge Builder Trust140,9750 00For
Equitable137,1440 00For

Showing the 25 largest of 119 asset managers. All 119 are in the interactive database (link above).

Largest Revolution Medicines, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 200,178,626 shares outstanding at the time of that meeting.

Fund voting reports: top Revolution Medicines, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 9.66%
2Fidelity 4.83%
3JANUS INVESTMENT FUND 2.51%
4BlackRock 2.10%
5T. Rowe Price 1.28%
6Charles Schwab 0.92%
7State Street 0.47%
8Columbia Threadneedle 0.43%
9Capital Group 0.40%
10Lord Abbett 0.35%
Institutional-manager reports: top Revolution Medicines, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 10.82%
2FARALLON CAPITAL MANAGEMENT, L.L.C. 7.06%
3Fidelity 5.19%
4BlackRock 3.38%
5Darwin Global Management, Ltd. 2.89%
6Paradigm Biocapital Advisors LP 2.54%
7Wellington 2.20%
8Nextech Invest Ltd. 2.00%
9State Street 2.00%
10T. Rowe Price 1.93%

Reported Revolution Medicines, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Revolution Medicines, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group16,719,886 8.35%Form 13F, quarter ended March 31, 2026
Entities affiliated with Farallon Capital Partners, L.P.14,476,064 7.23%Proxy statement (DEF 14A), table as of March 31, 2026
Baker Bros. Advisors LP11,443,357 5.72%Schedule 13G, filed August 14, 2026
Entities affiliated with Janus Henderson Group PLC11,356,054 5.67%Proxy statement (DEF 14A), table as of March 31, 2026
BlackRock11,212,706 5.60%Form 13F, quarter ended March 31, 2026
JANUS HENDERSON GROUP PLC9,766,496 4.88%Schedule 13G, filed May 15, 2026
FMR (Fidelity)8,464,314 4.23%Form 13F, quarter ended March 31, 2026
Thilo Schroeder, Ph.D.7,601,087 3.80%Proxy statement (DEF 14A), table as of March 31, 2026
Wellington Management6,027,819 3.01%Form 13F, quarter ended March 31, 2026
State Street4,402,662 2.20%Form 13F, quarter ended March 31, 2026

Percentages above are of 200,178,626 shares outstanding, as reported by Revolution Medicines, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Revolution Medicines, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 527 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 2,573 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — Revolution Medicines, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Revolution Medicines, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 22, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Revolution Medicines, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Revolution Medicines, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Revolution Medicines (RVMD) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/revolution-medicines-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.